GLP-1 Education · 043
REWIND: Use Trial Eligibility to Improve Cardiovascular Counseling
Examine population and endpoint differences before transferring a research result into clinical practice.
Dr. Sherry-Ann Brown, MD, PhD, FACC, FAHA
Keep the evidence precise
REWIND assessed dulaglutide in type 2 diabetes with cardiovascular disease or cardiovascular risk factors and showed a reduction in its primary cardiovascular composite. The original report describes the eligibility and followup. The patient conversation framework below is an original synthesis for thoughtful clinical application.
Examine the clinical match
Review the patient's diabetes status, cardiovascular diagnoses, risk profile, current treatment, and practical circumstances. Compare those features with the studied population and verify the exact product's current prescribing information. Identify why the proposed treatment is being considered for this patient. A focused explanation might connect a documented clinical concern, relevant medication evidence, and an agreed treatment goal. The patient should understand how the choice follows from their own condition and preferences. This promotes a meaningful conversation when several appropriate therapies may be available.
Discuss endpoints and uncertainty
Explain the trial's major cardiovascular event composite in plain language. If using an event rate or relative estimate, state the original timeframe and relevant population. Discuss what the finding contributes to the decision and what remains uncertain for an individual. Invite questions about administration, tolerability, access, and monitoring. Review other relevant aspects of prevention and diabetes care during the same conversation. This gives the patient a complete sense of the clinical purpose and the daily responsibilities involved in implementing the proposed treatment.
Build continuity around the decision
Record the evidence reviewed, the patient specific rationale, safety assessment, chosen regimen, and followup responsibilities. At later visits, review medication use and the barriers the patient actually encountered. Reassess the clinical plan when new findings appear or practical circumstances change. Communicate concise relevant updates to the other professionals involved. An evidence informed choice becomes durable when the team understands why it was made and when the patient can describe how it fits their care. This is particularly valuable during transitions between primary care, endocrinology, and cardiology.
Use eligibility to sharpen the discussion
Review how REWIND defined cardiovascular disease and risk factors before describing the trial as applicable to the patient. Record the features that matter for that comparison. If the patient has a substantially different clinical context, identify the additional evidence or guidance considered. This makes the explanation precise and helps the team assess future changes in the treatment rationale.
Apply the framework
A patient with type 2 diabetes and several cardiovascular risk factors asks about dulaglutide. Review their clinical history against REWIND eligibility, check current labeling, and discuss the outcome measured. Pair the evidence discussion with a practical plan for medication use, symptom reporting, and followup that the patient can realistically sustain.